Is long COVID the next global health crisis?

被引:26
作者
Faghy, Mark A. [1 ,2 ]
Owen, Rebecca [1 ,2 ]
Thomas, Callum [1 ,2 ]
Yates, James [1 ,2 ]
Ferraro, Francesco, V [1 ,2 ]
Skipper, Lindsay [3 ]
Barley-McMullen, Sarah
Brown, Darren A. [3 ,4 ]
Arena, Ross [2 ,5 ]
Ashton, Ruth E. M. [1 ,2 ]
机构
[1] Univ Derby, Sch Human Sci, Biomed Res Theme, Derby, England
[2] Hlth Living Pandem Event Protect HL PIVOT Network, Chicago, IL USA
[3] Long COVID Physio, London, England
[4] Chelsea & Westminster Hosp NHS Fdn Trust, Therapies Dept, London, England
[5] Univ Illinois, Chicago, IL USA
关键词
D O I
10.7189/jogh.12.03067
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The rapid development and deployment of coronavirus disease 2019 (COVID-19) vaccines should be heralded as a feat of true scientific collaboration that saved millions of lives [1]. Despite the success, vaccines do not offer complete protection against infection, mild, and severe disease [2-5] and the de-velopment of a long-term complex symptom profile, commonly referred to as long COVID [5,6]. Long CO-VID results from a positive infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19. It used ribonucleic acid (RNA), which is prone to replication and proliferation, leading to the transmission of variants that are a threat to global health. SARS-CoV-2 is known to evolve at an approximate rate of 1.1 x 10-3 substitutions per site per year, equivalent to a single substitution every 11 days [7]. Whilst not all mutations pose a threat to public and global health, previous variants including Omicron (B.1.1.529, BA.1, BA.1.1, BA.2, BA.3, BA.4, and BA.5 lineages) and Delta (B.1.617.2 and AY lineages) are widely regarded as variants of concern [8]. Data highlights that there is no difference in risk level between Delta and Omicron BA.1 variant among those that are triple-vaccinated [9]. These variants are characterised by several mutations that affect the spike protein and increase transmissibility [10], leading to the sustained and widespread transmission of acute infection which will inevitably result in increased pro-gression of long COVID. The latest data highlight that vaccines only offer a 15% reduction against developing long COVID and a 34% reduction in the risk of mortality [1]. Furthermore, clinical features are indistinguishable in those that were vaccinated and subsequently contracted SARS-CoV-2 compared with those with long COVID that were unvac-cinated [5]. While data sets remain infrequent, > 144 million people globally are living with multi -dimension-al and episodic symptoms that broadly impact functional status and quality of life [11]. This is compounded by economic and societal drivers contributing to an increasing burden of Long COVID in the global popula-sustained transmission of SARS-CoV-2, future variants of concern and confirmed projection of increas-Long COVID prevalence, pose a significant risk to public health.
引用
收藏
页数:6
相关论文
共 31 条
  • [1] Long COVID after breakthrough SARS-CoV-2 infection
    Al-Aly, Ziyad
    Bowe, Benjamin
    Xie, Yan
    [J]. NATURE MEDICINE, 2022, 28 (07) : 1461 - +
  • [2] [Anonymous], 2018, Lancet Infectious Diseases, V18, P1191
  • [3] [Anonymous], 2016, oxfordreference.com dictionary, DOI DOI 10.1093/OI/AUTHORITY.20110803100109997
  • [4] COVID-19 and the long-term cardio-respiratory and metabolic health complications
    Ashton, Ruth
    Ansdell, Paul
    Hume, Emily
    Maden-Wilkinson, Tom
    Ryan, Declan
    Tuttiett, Esme
    Faghy, Mark
    [J]. REVIEWS IN CARDIOVASCULAR MEDICINE, 2022, 23 (02)
  • [5] The delivery plan for tackling the covid-19 backlog of elective care falls short
    Bagenal, Jessamy
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2022, 377
  • [6] Conceptualising Long COVID as an episodic health condition
    Brown, Darren A.
    O'Brien, Kelly K.
    [J]. BMJ GLOBAL HEALTH, 2021, 6 (09):
  • [7] Chemaitelly H, 2022, LANCET, V399, P771, DOI 10.1016/S0140-6736(22)00277-X
  • [8] Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review
    Chen, Chen
    Haupert, Spencer R.
    Zimmermann, Lauren
    Shi, Xu
    Fritsche, Lars G.
    Mukherjee, Bhramar
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2022, 226 (09) : 1593 - 1607
  • [9] SARS-CoV-2 Vaccines
    Creech, C. Buddy
    Walker, Shannon C.
    Samuels, Robert J.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 325 (13): : 1318 - 1320
  • [10] Characterizing long COVID in an international cohort: 7 months of symptoms and their impact
    Davis, Hannah E.
    Assaf, Gina S.
    McCorkell, Lisa
    Wei, Hannah
    Low, Ryan J.
    Re'em, Yochai
    Redfield, Signe
    Austin, Jared P.
    Akrami, Athena
    [J]. ECLINICALMEDICINE, 2021, 38